Close Menu

hemophilia

Alnylam Pharmaceuticals this week provided new guidance on its key drug-development programs, noting that its flagship transthyretin-mediated amyloidosis therapy ALN-TTR02 remains poised to enter phase III testing by the end of next year, and that the development of a subcutaneou

Alnylam Pharmaceuticals this week released new preclinical data on its GalNAc conjugate delivery technology, showing that the approach could permit subcutaneous delivery of siRNAs with a wide therapeutic index.

Alnylam Pharmaceuticals this week announced new preclinical data showing that its investigational RNAi-based treatment for hemophilia, ALN-AT3, could achieve target gene knockdown after subcutaneous administration to both mice and non-human primates.

Alnylam Pharmaceuticals announced this week that it has added ALN-APC, an siRNA-based treatment for hemophilia, to its formal drug-development pipeline.

The study, which sequenced and characterized 20 individual genomes, is part of a larger effort at Duke that aims to sequence around 200 genomes and 500 exomes from various disease cohorts including schizophrenia, epilepsy, ALS, and HIV.

The companies will develop and use Genedata's Biologics Data Platform at Bayer Schering R&D sites in Europe and the US.

Russian and American researchers reported today that Alexei and Anastasia Romanov carried a mutation in the blood coagulation factor gene F9 that causes hemophilia B, or "Christmas disease."

Pages

Researchers are sampling the wild relatives of modern crops to try to preserve genetic diversity, NPR reports.

MIT's Search for Extraterrestrial Genomes is developing sequencing tools to use to try to detect whether there is any life on Mars, Quartz reports.

Undark reports on a bill introduced this year to the US House of Representatives to strengthen scientific integrity.

In Genome Research this week: post-zygotic mutations in diabetes development, single-cell RNA sequencing study of aging, and more.